ArticleMedicine2026
Serum 8-hydroxy-2-deoxyguanosine levels in pediatric acute lymphoblastic leukemia: A retrospective case-control study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oxidative stress contributes to carcinogenesis through deoxyribonucleic acid (DNA) damage, and 8-hydroxy-2-deoxyguanosine (8-OHdG) is a well-established biomarker of oxidative DNA injury. This study aimed to evaluate oxidative stress in pediatric acute lymphoblastic leukemia (ALL) by measuring serum 8-OHdG levels before and after chemotherapy. This retrospective case-control study included 32 children diagnosed with ALL and 30 age- and sex-matched healthy controls. Serum 8-OHdG levels were measured using an enzyme-linked immunosorbent assay prior to treatment and after the initiation of maintenance therapy, approximately one month following intensive chemotherapy. Comparisons between groups were performed using the Mann-Whitney U test, and within-patient changes were assessed using the Wilcoxon signed-rank test. Pretreatment serum 8-OHdG levels were significantly higher in children with ALL compared with controls (P < .001), indicating increased oxidative DNA damage. Serum 8-OHdG levels significantly decreased after chemotherapy in children with ALL (P < .001). However, no statistically significant difference was observed between post-treatment 8-OHdG levels and those of the control group (P = 1.0). No significant associations were found between pretreatment 8-OHdG levels and white blood cell count or body mass index. Children with ALL exhibit significantly elevated serum 8-OHdG levels, supporting a role for oxidative stress in disease pathogenesis. The reduction in 8-OHdG levels following chemotherapy suggests a potential relationship between treatment response and oxidative DNA damage, indicating that 8-OHdG may serve as a useful biomarker in pediatric ALL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.